-
Mashup Score: 2
Andrew Davies, MRCP, PhD, University of Southampton, Southampton, UK, discusses results from a long-term follow-up of the Phase III REMoDL-B…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1Pushing the boundaries at the 2023 BSH ASM - 1 year(s) ago
The atmosphere at this year’s Annual Scientific Meeting (ASM) was a particularly energetic mix of excitement and anticipation, alongside some trenchant discussion of the challenges facing the haematology workforce. As nearly 1,600 delegates descended on the International Convention Centre (ICC) in Birmingham under dampish skies, there was a fair bit of side chatter about workloads and staffing…
Source: BSHCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0BSH at 60 - 1 year(s) ago
The first meeting of the British Society for Haematology (BSH) took place on 19 November 1960. For 60 years BSH has been dedicated to helping members support people with blood disorders and diseases. Our 60th anniversary is a time for recognising the breadth of roles within the multidisciplinary haematology team and acknowledging the contribution of haematology professionals to the advancement…
Source: BSHCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Kim Linton, MBChB, MRCP, PhD, FRCP, University of Manchester and The Christie NHS Foundation Trust, Manchester, UK, shares some insights…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1Preventing the risk of infection in patients with B-cell malignancies in the era of novel agents - 1 year(s) ago
Robert Weinkove, MA (Cantab), MBBS (Hons), PhD, FRACP, FRCP, Malaghan Institute of Medical Research, Wellington, New Zealand, discusses the importance…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1Patient & disease-related factors to consider when selecting patients with MDS for transplant - 1 year(s) ago
Pramila Krishnamurthy, MA, FRCPath, MRCP, PhD, King’s College Hospital NHS Foundation Trust, London, UK, discusses important factors to consider when…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Manoj Raghavan, MBBS, PhD, FRCPath, MRCP, CCST, University of Birmingham, Birmingham, UK, shares some insights into the Phase II REPAIR-MDS…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 2Factors to consider when selecting between continuous and fixed-duration therapy in CLL - 1 year(s) ago
Talha Munir, MBBS, Leeds Teaching Hospitals NHS Trust, Leeds, UK, shares some insights into factors to consider when selecting between…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1BSH 2023 | VJHemOnc - 1 year(s) ago
The 63rd Annual Scientific Meeting of the British Society for Haematology (BSH) is taking place on 23-25 April 2023 in Birmingham, UK, and will bring hematology professionals together to discuss advances in the field. View all videos The…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0BSH at 60 - 1 year(s) ago
The first meeting of the British Society for Haematology (BSH) took place on 19 November 1960. For 60 years BSH has been dedicated to helping members support people with blood disorders and diseases. Our 60th anniversary is a time for recognising the breadth of roles within the multidisciplinary haematology team and acknowledging the contribution of haematology professionals to the advancement…
Source: BSHCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
The REMoDL-B trial evaluated whether there was any benefit to adding bortezomib to R-CHOP in patients with various subtypes of DLBCL. Find out more in our interview with Andrew Davies (@unisouthampton): 👉https://t.co/g7ntbMIqp2👈 @BritSocHaem #BSH2023 #LymSM #DLBCL